Plain-English translation of NCT07778524 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a pilot study testing whether a single dose of alpelisib — a medication that temporarily increases insulin resistance — can help doctors better measure how well your pancreas produces insulin when you eat. Right now, the gold standard test requires continuous glucose infusion in a hospital, which is complex and not practical for routine use. This new approach aims to make the measurement simpler and more accessible.
Type 2 diabetes develops when the pancreas can't produce enough insulin to keep up with the body's demands. Being able to accurately measure pancreatic function early on could help doctors predict who is at risk for diabetes and track whether treatments are working — but current methods are too difficult to use widely in research and clinical practice.
You likely qualify if…
You likely don't qualify if…
You will stay overnight in a hospital research unit for about 30 hours. On the morning of day one, you'll undergo the standard hospital test (glucose infusion) to measure how well your pancreas responds to high blood sugar. That evening, you'll take a single dose of the medication, and the next morning you'll eat a test meal while doctors measure your insulin levels. This allows researchers to see whether the medication helps create a better challenge that more accurately reflects pancreatic function.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States